MDT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Medtronic is a solid long-term income stock, but at the current pre-market price near $80.62 it is not a clear buy for a Beginner investor who wants a long-term position and is not waiting for a better entry. I would hold rather than buy aggressively right now. The business is improving, dividend support is strong, and valuation looks reasonable, but analyst sentiment is mixed and upside appears moderate rather than compelling from here.
MDT is trading in a constructive but not strongly bullish setup. Pre-market price is 80.62, just above the pivot at 78.26 and below resistance R1 at 81.90. MACD histogram is positive at 0.79, which supports near-term bullish momentum, but it is contracting, so the move is losing strength. RSI_6 at 57.84 is neutral to mildly positive, and moving averages are converging, suggesting a coiling phase rather than a strong breakout trend. The stock has a 60% modeled chance to gain modestly in the near term, but the technical picture does not show a high-conviction entry.
["Medtronic reported an 8.4% sales increase for fiscal 2026, its strongest growth rate in a decade.", "Hugo robotic surgery platform received FDA approval for urologic procedures, expanding growth opportunities.", "The company is set for its 50th consecutive annual dividend increase, reinforcing long-term shareholder appeal.", "Hedge funds are buying, with buying amount up 167.88% over the last quarter.", "BTIG upgraded MDT to Buy and sees the current setup as undervalued relative to peers.", "News flow highlights improving growth momentum and a strong product cycle."]
["Several analysts cut price targets recently, including Goldman Sachs, Truist, UBS, Baird, Stifel, Bernstein, Needham, and Mizuho.", "Consensus tone remains mixed, with multiple Neutral/Hold ratings still in place.", "EPS guidance for FY27 was viewed as softer than revenue growth, with margin pressure cited by analysts.", "Congress trading shows 1 sale and 0 purchases over the last 90 days, which leans cautious.", "Insider activity is neutral, with no strong buying signal from insiders.", "Price action is still below nearby resistance and not showing strong breakout momentum."]
Latest quarter appears to be Q4 FY2026 based on the analyst notes. The quarter was broadly positive on the top line, with revenue and organic growth ahead of consensus and sales growth reaching 8.4% for fiscal 2026, a decade high. However, EPS guidance for FY27 was more cautious than revenue trends, and analysts flagged lower gross and operating margins. In short, the latest quarter showed improving growth momentum, but profitability and margin expansion remain the key concern.
Recent analyst sentiment is mixed-to-cautious. BTIG upgraded MDT to Buy, while Needham and Mizuho remain constructive, but Goldman Sachs, UBS, Truist, Baird, and Stifel all lowered price targets and mostly kept Neutral/Hold views. Price targets were trimmed across the Street, signaling reduced near-term upside expectations. Wall Street pros see the positives as improving organic growth, strong product cycle potential, and an attractive valuation/dividend profile. The negatives are slower EPS growth, margin pressure, and uncertainty around how quickly Medtronic can convert revenue improvement into earnings acceleration.
